Article

[Three cases of idiopathic thrombocytopenic purpura showing an increase in the platelet count following clarithromycin treatment].

Department of Internal Medicine, Hokkaido Social Insurance Hospital.
[Rinshō ketsueki] The Japanese journal of clinical hematology 11/2003; 44(10):1044-6.
Source: PubMed

ABSTRACT Macrolides have immuno-modulatory effects as well as anti-bacterial effects. We successfully treated three idiopathic thrombocytopenic purpura (ITP) patients with clarithromycin (CAM). Case 1: A 69-year-old male ITP patient was treated with CAM at a dose of 400 mg/day. His platelet count increased from 5.6 x 10(4)/microliter to 10.1 x 10(4)/microliter. Case 2: A 72-year-old male ITP patient was treated with CAM at the same dose. The platelet count increased from 1.3 x 10(4)/microliter to 12.3 x 10(4)/microliter. Case 3: A 68-year-old female ITP patient was treated with CAM at the same dose. The platelet count increased from 2.3 x 10(4)/microliter to 13 x 10(4)/microliter. These facts suggest that CAM is useful in the treatment of ITP.

0 Followers
 · 
122 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of anti-inflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed to assess the usefulness of macrolides in other inflammatory diseases including skin and hair disorders, such as rosacea, psoriasis, pityriasis rosea, alopecia areata, bullous pemphigoid, and pityriasis lichenoides. This paper summarizes a collection of clinical studies and case reports dealing with the potential benefits of macrolides antibiotics in the treatment of selected dermatoses which have primarily been classified as noninfectious and demonstrating their potential for being disease-modifying agents.
    Mediators of Inflammation 05/2012; 2012:159354. DOI:10.1155/2012/159354 · 2.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immune thrombocytopenic purpura (ITP) is an acquired disorder characterized by thrombocytopenia, increased platelet destruction, and the inhibition of platelet production by specific autoantibodies. Previous studies have reported improvements in ITP following the eradication of Helicobacter pylori (H. pylori) infection. We, herein, investigated the relationship between initial therapy for ITP and lymphocyte counts at diagnosis. We retrospectively examined 52 adult patients with ITP between March 1998 and March 2013. Standard H. pylori eradication therapy was performed in 31 patients, and lymphocyte counts were compared before and after this therapy. At the diagnosis of ITP, lymphocyte counts in H. pylori-infected patients were significantly higher than those in H. pylori-negative patients (1.92 ± 0.68 × 10(9)/L vs. 1.42 ± 0.67 × 10(9)/L; p = 0.010). H. pylori eradication was successful in 6/11 patients (54.5 %) and the platelet count increased in 4/11 H. pylori-positive patients (36.4 %) who received eradication therapy. On the other hand, eradication therapy was also administered to 15 patients without H. pylori infection, and responses were obtained in some H. pylori-negative patients receiving eradication therapy (9/15). Furthermore, lymphocyte counts were significantly higher in patients who achieved a complete response receiving H. pylori eradication therapy than in patients who did not achieve a complete response (2.4 ± 0.59 × 10(9)/L vs. 1.37 ± 0.60 × 10(9)/L, p = 0.0023). The response of ITP patients to the initial treatment may be predicted by measuring the lymphocyte count at diagnosis. Further studies that analyze lymphocyte subsets and the cytokine network are needed to elucidate the underlying mechanisms.
    International Journal of Hematology 03/2015; 101(3):268-72. DOI:10.1007/s12185-015-1737-9 · 1.68 Impact Factor
  • Journal of the Formosan Medical Association 03/2014; 113(3):197-8. DOI:10.1016/j.jfma.2011.08.035 · 1.70 Impact Factor